The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats

Behavioural Brain Research

Volumn 243, Issue 1, 2013, Pages 6-15

  Mulcahy, Pádraig ^a   O'Doherty, Aideen ^a   Paucard, Alexia ^a   O'Brien, Timothy ^a   Kirik, Deniz ^b   Dowd, Eilís ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b LUND UNIVERSITY   (Sweden)

Author keywords

AAV synuclein; Animal models; Motor function; Parkinson's disease; Rotenone

Indexed keywords

ALPHA SYNUCLEIN; PESTICIDE; ROTENONE; TYROSINE 3 MONOOXYGENASE;

ALPHA SYNUCLEINOPATHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE ASSOCIATION; GENETIC ASSOCIATION; GENOTYPE ENVIRONMENT INTERACTION; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OSMOTIC MINIPUMP; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; WEIGHT REDUCTION;

ALPHA-SYNUCLEIN; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; GENE-ENVIRONMENT INTERACTION; GENETIC VECTORS; INFUSION PUMPS, IMPLANTABLE; INSECTICIDES; MALE; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; ROTENONE; SUBSTANTIA NIGRA; WEIGHT LOSS;

EID: 84872532026     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.12.051     Document Type: Article

References (47)

1. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging 2003, 24:197-211.
2. Jankovic J. Parkinson's disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery and Psychiatry 2008, 79:368-376.
3. Vance J.M., Ali S., Bradley W.G., Singer C., Di Monte D.A. Gene-environment interactions in Parkinson's disease and other forms of parkinsonism. Neurotoxicology 2010, 31:598-602.
4. Gao H.M., Hong J.S. Gene-environment interactions: key to unraveling the mystery of Parkinson's disease. Progress in Neurobiology 2011, 94:1-19.
5. Tanner C.M., Kamel F., Ross G.W., Hoppin J.A., Goldman S.M., Korell M., et al. Rotenone, paraquat, and Parkinson's disease. Environmental Health Perspectives 2011, 119:866-872.
6. Svenson L.W., Platt G.H., Woodhead S.E. Geographic variations in the prevalence rates of Parkinson's disease in Alberta. Canadian Journal of Neurological Sciences 1993, 20:307-311.
7. Imaizumi Y. Geographical variations in mortality from Parkinson's disease in Japan, 1977-1985. Acta Neurologica Scandinavica 1995, 91:311-316.
8. Goldman S.M., Tanner C.M., Oakes D., Bhudhikanok G.S., Gupta A., Angston J.W. Head injury and Parkinson's disease risk in twins. Annals of Neurology 2006, 60:65-72.
9. Van Den Eeden S.K., Tanner C.M., Bernstein A.L., Fross R.D., Leimpeter A., Bloch D.A., et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. American Journal of Epidemiology 2003, 157:1015-1022.
10. Sato S., Hattori N. Genetic mutations and mitochondrial toxins shed new light on the pathogenesis of Parkinson's disease. Parkinson's Disease 2011, 2011:979231.
11. Gorell J.M., Rybicki B.A., Johnson C.C., Peterson E.L. Smoking and Parkinson's disease: a dose-response relationship. Neurology 1999, 52:115-119.
12. Ross G.W., Petrovitch H. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drugs and Aging 2001, 18:797-806.
13. Bove J., Prou D., Perier C., Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2005, 2:484-494.
14. Blesa J., Phani S., Jackson-Lewis V., Przedborski S. Classic and new animal models of Parkinson's disease. Journal of Biomedicine and Biotechnology 2012, 845618.
15. Grunblatt E., Mandel S., Youdim M.B. MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategies. Journal of Neurology 2000, 247(Suppl. 2):II95-II102.
16. Lane E., Dunnett S. Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic?. Psychopharmacology 2008, 199:303-312.
17. Linazasoro G. Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions. Movement Disorders 2004, 19:743-754.
18. Willis G.L., Kennedy G.A. The implementation of acute versus chronic animal models for treatment discovery in Parkinson's disease. Reviews in the Neurosciences 2004, 15:75-87.
19. Biglan K.M., Ravina B. Neuroprotection in Parkinson's disease: an elusive goal. Seminars in Neurology 2007, 27(106):112.
20. Kieburtz K., Ravina B. Why hasn't neuroprotection worked in Parkinson's disease?. Nature Clinical Practice Neurology 2007, 3:240-241.
21. Meredith G., Sonsalla P., Chesselet M.-F. Animal models of Parkinson's disease progression. Acta Neuropathologica 2008, 115:385-398.
22. Mulcahy P., Walsh S., Paucard A., Rea K., Dowd E. Characterisation of a novel model of Parkinson's disease by intra-striatal infusion of the pesticide rotenone. Neuroscience 2011, 181:234-242.
23. Grimm D., Kern A., Rittner K., Kleinschmidt A. Novel tools for production and purification of recombinant adenoassociated virus vectors. Human Gene Therapy 1998, 9:2745-2760.
24. Dowd E., Monville C., Torres E.M., Dunnett S.B. The Corridor Task: a simple test of lateralised response selection sensitive to unilateral dopamine deafferentation and graft-derived dopamine replacement in the striatum. Brain Research Bulletin 2005, 68:24-30.
25. Fitzsimmons D.F., Moloney T.C., Dowd E. Further validation of the corridor task for assessing deficit and recovery in the hemi-Parkinsonian rat: restoration of bilateral food retrieval by dopamine receptor agonism. Behavioural Brain Research 2006, 169:352-355.
26. Olsson M., Nikkhah G., Bentlage C., Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. Journal of Neuroscience 1995, 15:3863-3875.
27. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000, 39:777-787.
28. Greene J.G., Noorian A.R., Srinivasan S. Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease. Experimental Neurology 2009, 218:154-161.
29. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T.E., Muzyczka N., et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. Journal of Neuroscience 2002, 22:2780-2791.
30. Yamada M., Iwatsubo T., Mizuno Y., Mochizuki H. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. Journal of Neurochemistry 2004, 91:451-461.
31. Gorbatyuk O.S., Li S., Sullivan L.F., Chen W., Kondrikova G., Manfredsson F.P., et al. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:763-768.
32. Azeredo da Silveira S., Schneider B.L., Cifuentes-Diaz C., Sage D., Abbas-Terki T., Iwatsubo T., et al. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Human Molecular Genetics 2009, 18:872-887.
33. Ulusoy A., Decressac M., Kirik D., Bjorklund A. Viral vector-mediated overexpression of alpha-synuclein as a progressive model of Parkinson's disease. Progress in Brain Research 2010, 184:89-111.
34. Koprich J.B., Johnston T.H., Huot P., Reyes M.G., Espinosa M., Brotchie J.M. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein. PLoS One 2011, 6:e17698.
35. Lindgren H.S., Lelos M.J., Dunnett S.B. Do alpha-synuclein vector injections provide a better model of Parkinson's disease than the classic 6-hydroxydopamine model?. Experimental Neurology 2012, 237:36-42.
36. Ferrante R.J., Schulz J.B., Kowall N.W., Beal M.F. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Research 1997, 753:157-162.
37. Antkiewicz-Michaluk L., Karolewicz B., Romanska I., Michaluk J., Bojarski A.J., Vetulani J. 1-Methyl-1,2,3,4-tetrahydroisoquinoline protects against rotenone-induced mortality and biochemical changes in rat brain. European Journal of Pharmacology 2003, 466:263-269.
38. Alam M., Schmidt W.J. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats. Behavioural Brain Research 2004, 153:439-446.
39. Lapointe N., St-Hilaire M., Martinoli M.G., Blanchet J., Gould P., Rouillard C., et al. Rotenone induces non-specific central nervous system and systemic toxicity. FASEB Journal 2004, 18:717-719.
40. Cabral G.A., Harmon K.N., Carlisle S.J. Cannabinoid-mediated inhibition of inducible nitric oxide production by rat microglial cells: evidence for CB1 receptor participation. Advances in Experimental Medicine and Biology 2001, 493:207-214.
41. Iseki E., Kato M., Marui W., Ueda K., Kosaka K. A neuropathological study of the disturbance of the nigro-amygdaloid connections in brains from patients with dementia with Lewy bodies. Journal of the Neurological Sciences 2001, 185:129-134.
42. Raff M.C., Whitmore A.V., Finn J.T. Axonal self-destruction and neurodegeneration. Science 2002, 296:868-871.
43. Morfini G., Pigino G., Opalach K., Serulle Y., Moreira J.E., Sugimori M., et al. 1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:2442-2447.
44. Chu Y., Morfini G.A., Langhamer L.B., He Y., Brady S.T., Kordower J.H. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain 2012, 135:2058-2073.
45. Cookson M.R., van der Brug M. Cell systems and the toxic mechanism(s) of alpha-synuclein. Experimental Neurology 2008.
46. Degli Esposti M. Inhibitors of NADH-ubiquinone reductase: an overview. Biochimica et Biophysica Acta 1998, 1364:222-235.
47. Cannon J.R., Geghman K.D., Tapias V., Sew T., Dail M.K., Li C., et al. Expression of human E46K-mutated alpha-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment. Experimental Neurology 2012, 240C:44-56.